Related Experiment Video

Updated: Sep 22, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here

Tiago Tribolet de Abreu1

  • 1Serviço de Medicina, Hospital do Espírito Santo-Évora E.P.E, Évora, Portugal. ttabreu@hevora.min-saude.pt.

Heart Failure Reviews
|May 23, 2022
PubMed

Insights

Heart failure with preserved ejection fraction (HFpEF) lacked effective treatments for decades. The EMPEROR-Preserved trial demonstrated empagliflozin significantly improved outcomes in HFpEF patients, marking a therapeutic breakthrough.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • Heart failure with preserved ejection fraction (HFpEF), historically termed diastolic heart failure, has been recognized for over 50 years.
  • Despite extensive research, no therapy has definitively improved outcomes for HFpEF patients.
  • Challenges in definition and diagnosis have historically hindered therapeutic development for HFpEF.

Purpose of the Study:

  • To review the historical context and diagnostic evolution of HFpEF.
  • To critically analyze the findings of the EMPEROR-Preserved Trial.
  • To assess the impact of empagliflozin on HFpEF patient outcomes.

Main Methods:

  • Review of historical literature on HFpEF.
  • Critical analysis of the EMPEROR-Preserved Trial methodology and results.
  • Evaluation of empagliflozin's efficacy in a large HFpEF patient cohort.

Main Results:

  • The EMPEROR-Preserved Trial is the first study to demonstrate a significant improvement in outcomes for patients with HFpEF.
  • Empagliflozin showed a positive impact on key clinical endpoints in the HFpEF population.
  • The trial provides novel evidence for therapeutic intervention in HFpEF.

Conclusions:

  • Empagliflozin represents a significant advancement in the treatment of HFpEF.
  • The EMPEROR-Preserved Trial results offer a new therapeutic avenue for managing HFpEF.
  • Further research should build upon these findings to optimize HFpEF care.

Keywords:
Diastolic heart failureHeart failurePreserved ejection fraction

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
69
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
48
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
88
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
62